Tech Investing and Innovation by Delian Asparouhov

Delian Asparouhov is a Partner at Founders Fund, managing part of a portfolio exceeding $3 billion. He previously worked at Khosla Ventures and co-founded healthcare startup Nightingale, giving him both operator and investor credentials. He also co-founded space manufacturing company Varda, which raised $53 million in Series A funding in 2021.

Asparouhov has been involved in large venture rounds including $110 million Series C and $190 million Series C financings, covering deep tech, fintech, and crypto-adjacent startups. His investment philosophy focuses on transformative industries like blockchain, aerospace, and biotech.

His personal net worth is not publicly disclosed, but as a partner at a multibillion-dollar venture fund, he earns substantial carried interest from successful exits. Achievements include driving growth for companies valued in the hundreds of millions, co-founding one of the first space manufacturing firms, and being a highly visible voice in early-stage funding. He has also become a public commentator on the convergence of Bitcoin, sovereign finance, and venture capital, making his profile relevant to the crypto investment landscape.

  • Igor Krasulya
  • 25.09.2026
Delian Asparouhov: Varda secures $51.8 million this year with additional $48.8 million requested
Delian Asparouhov announced that Varda, a venture focused on building drug manufacturing facilities in space, is making progress with drugs now headed to clinics. Asparouhov also stated that ...
  • Igor Krasulya
  • 04.08.2026
Google spent $45 billion on capex last quarter, Delian Asparouhov notes
Delian Asparouhov highlights that in 2012, Peter Thiel criticized Google for holding $30 billion in cash, suggesting it acted more like a bank than a tech company due to a lack of investment ...
  • Anastasiia Chabaniuk
  • 31.07.2026
Delian Asparouhov: Wall Street success often follows early career setbacks
Delian Asparouhov points out that many of the most accomplished professionals on Wall Street and in the hedge fund industry have experienced major career setbacks early on. He suggests that ...
  • Olga Shendetskaya
  • 20.05.2026
AMCA secures $300 million Series B at $1 billion valuation, Delian Asparouhov notes
Delian Asparouhov reflects on his experience working with Jai, describing him as a favored seed investor for many years. Asparouhov states that Jai’s decision to shut down his fund was ...
  • Eugene Komchuk
  • 14.05.2026
Delian Asparouhov: Anthropic run-rate estimated at $60 billion, Keytruda at $25 billion
Delian Asparouhov draws attention to the notable run-rates of two major entities. Anthropic is estimated to have a run-rate of approximately $60 billion, while Keytruda, a drug that was improved ...